A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer

Annals of Oncology

Volumn 13, Issue 11, 2002, Pages 1730-1736

  Mustacchi, G ^a   Muggia, M ^a   Milani, S ^a   Ceccherini, R ^a   Leita, M L ^a   Dellach, C ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Chemotherapy; Cisplatin; Metastatic breast cancer; Vinorelbine

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLUTETHIMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MEGESTROL; METHYLPREDNISOLONE; METOCLOPRAMIDE; NAVELBINE; PACLITAXEL; SEROTONIN ANTAGONIST; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCORTICOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; METASTASIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0036861025     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf290     Document Type: Article

References (32)

1. Mouridsen HT. New cytotoxic drugs in the treatment of breast cancer. Acta Oncol 1990; 29: 257-285.
2. Sledge GW Jr, Loehrer PJ Sr, Roth BJ et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988; 6: 1811-1814.
3. Llombart-Cussac A, Spielmann M, Dohollou N et al. Cis-platinum-taxotere phase I/II trial in patients with anthracycline-resistant advanced breast cancer (ENG). Proc Am Soc Clin Oncol 1997; 16: 629.
4. Bernard A, Antoine EC, Gozy M et al. Docetaxel and cisplatin in anthracycline-pretreated advanced breast cancer: results of a phase II pilot study. Proc Am Soc Clin Oncol 1998; 17: 128a (Abstr 491).
5. Antoine EC, Gozy M, Benhammouda A et al. A phase II study of docetaxel and cisplatin in anthracycline-pretreated metastatic breast cancer: preliminary results (ENG). In Khayat D, Hortobagy G (eds). Proceedings of the Seventh International Congress on Anticancer Treatment, Paris, France, 3-6 February, 1997. Paris, France: Comptoir S. Sebastien 1997; 29 (Abstr O55).
6. Nagourney RA, Link JS, Blitzer JB et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer. J Clin Oncol 2000; 18: 2245-2249.
7. Canobbio L, Boccardo F, Pastorino G et al. Phase II study of navelbine in advanced breast cancer. Semin Oncol 1989; 16 (Suppl. 4): 33-36.
8. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-1252.
9. Terenziani M, Bonadonna G, Brambilla C et al. Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996; 39: 285-291.
10. Bruno S, Lira Puerto VL, Mickewicz E et al. Phase II study of weekly vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. Am J Clin Oncol 1995; 18: 392-396.
11. Garcia-Conde J, Lluch A, Martin M et al. Phase II study of navelbine in previously untreated advanced breast cancer. Ann Oncol 1994; 5 (Suppl. 9): 854-857.
12. Romero A, Rabinovich MG, Vallejo CT et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336-341.
13. Weber BL, Vogel C, Jones S et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722-2730.
14. Spielmann M, Dorval T, Turpin F et al. Phase II trial of vinorelbine/ doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994; 12: 1764-1770.
15. Escudero P, Bueso P, Mayordomo JI et al. Docetaxel + vinorelbine is an active combination for patients with anthracycline-refractory metastatic breast cancer. Results of a phase II trial. Proc Am Soc Clin Oncol 1998; 17: 139a (Abstr 529).
16. Fumoleau P, Fety R, Delacroix V et al. Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology 1997; 6: 29-31.
17. Botto HG, Botto ME, Otegui ML et al. Taxotere vs vinorelbine and taxol in patients with metastatic breast cancer anthracycline resistant. Proc Am Soc Clin Oncol 1998; 17: 130a (Abstr 498).
18. Romero Acuna L, Langhi M, Perez J et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999; 17: 74-81.
19. Kourousis C, Kakolyris S, Androulakis N et al. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am J Clin Oncol 1998; 21: 226-232.
20. Chadjaa M, Izzo J, May-Levin F et al. Preliminary data on 4′epiadriamycin-vinorelbine: a new active combination in advanced breast cancer. Proc Am Soc Clin Oncol 1993; 12: 88 (Abstr 152).
21. Mustacchi G, Milani S, Sandri P et al. Cisplatin-vinorelbine: a new active combination in metastatic breast cancer. Breast Cancer Res Treat 1994; 32 (Suppl): 33 (Abstr 30).
22. Mustacchi G, Ceccherini R, Muggia M et al. Cisplatinum and vinorelbine (CV) in metastatic breast cancer (MBC) after anthracycline failure. Proc Am Soc Clin Oncol 1999; 18: 135a (Abstr 518).
23. Dabaja BS, Shamseddine AI, Salem ZMK et al. Treatment of metastatic breast cancer with vinorelbine and cisplatinum: a clinical phase II trial. In Khayat D, Hortobagy G (eds). Proceedings of the Fifth International Congress on Anticancer Treatment (SOMPS), Paris, France, 3-6 February, 1995. Paris, France: Comptoir S. Sebastien 1995; (Abstr P444).
24. Shamseddine AI, Taher A, Dabaja B et al. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999; 3: 298-302.
25. Ray-Coquard I, Biron P, Bachelot T et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 1998; 82: 134-140.
26. Gunel N, Akali Z Yamac D et al. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 2000; 86: 283-285.
27. Vassilomanolakis M, Koumakis G, Barbounis V et al. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol 2000; 11: 1155-1160.
28. Hochster H, Wasserheit C, Siddiqui N et al. Vinorelbine/cisplatin therapy of locally advanced and metastatic cancer: an active regimen. Proc Am Soc Clin Oncol 1997; 16: 173a (Abstr 606).
29. Audhuy B, Husseini F, Dreyfus B et al. Phase II trial of navelbine and cisplatin in first-line chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17: 127a (Abstr 487).
30. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
31. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-159.
32. Kaplan E, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.